Amgen and MBC BioLabs Extend the Deadline for the 2019 Golden Ticket Competition

A Golden Ticket offers:  
  • Priority admission/renewal for one year's use of MBC BioLabs lab bench and Fast-track core facility, providing everything your startup needs to be successful
  • Unique access to Amgen scientific and business leaders
Deadline to apply for an Amgen Golden Ticket has been extended to MAY 3, 2019. To apply, submit your non-confidential company presentation HERE.  Amgen will notify the Golden Ticket winners by June 2019.
ChemoMetec Sponsors MBC BioLabs

ChemoMetec has generously placed a NucleoCounter® NC-200™ at MBC BioLabs San Francisco and San Carlos. The NucleoCounter® NC-200™ is a high precision automated cell counter utilizing state-of-the-art image cytometry. The Via1-Cassette™ used for automated staining and sample handling is volume calibrated to ensure high precision and reproducibility. With user adaptable protocols and specialized assays for aggregated cells and cells on microcarriers, the Automated Cell Counter NucleoCounter® NC-200™ provides an all-in-one solution for cell counting and cell viability determinations.

 Lunch Seminar with UCSF:
Proof of Concept and Growth: Using Data to Raise Capital and Beyond
May 15, 2019
12:00 to 1:00 PM

MBC BioLabs - 953 Indiana Street, San Francisco
Lunch served

Isabel Elaine Allen is Professor of Biostatistics and Epidemiology at UCSF, Mentor in Quantitative Biosciences and the Catalyst program at UCSF, and a consultant for CTSI at UCSF where she was Consultant of the Year for 2015-2016.  Dr. Allen is also Emeritus Professor of Statistics and Entrepreneurship at Babson College.  She founded and led several biotechnology companies, serves on the board and advises several non-profit organizations and analytic & biotechnology companies, and is also an angel investor. She is Co-Director of the Babson Survey Research Group and has received multiple research grants to design and conduct surveys on online education and entrepreneurship worldwide. She is a Fellow of the American Statistical Association. She has published widely on statistical issues in meta-analysis, analytics, survey research, data visualization, proof of concept and clinical research methodology. She serves on several NIH panels on best practices in statistics and evidence-based research and consults for several biotechnology/pharmaceutical companies. She received her PhD from Cornell University.

Christopher A. Seaman earned his master's degree in mathematics and cryptography, and is ABD in mathematics, from the City University of New York.  Prior to moving to San Francisco, Mr. Seaman taught statistics at John Jay College of Law in NYC and at Babson College in Wellesley, MA.  He also consulted on data management and statistics for several biotechnology companies.  Mr. Seaman was a research fellow at eBay prior to joining Atlassian where he was lead data scientist and was previously the lead on growth monetization for Dropbox. He lead each of these groups through their company's IPO's creating plans for each company's future growth and monetization.

Lunch Seminar with WSGR:
Safe vs. Convertible Notes vs. Priced Rounds
May 21, 2019
12:00 to 1:00 PM

MBC BioLabs - 733 Industrial Road, San Carlos
Lunch served

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he has worked since 2000 with a focus on advising life science companies. He is a trusted advisor and outside general counsel to founders, management teams and boards of directors on company formations, financing and strategic transactions, cross-border deals, and corporate governance throughout a company's lifecycle. His expertise includes venture financings, mergers and acquisitions, strategic corporate relationships, and public offerings. He also represents incubators and accelerators working with startups and venture capital in their formation, securities offerings and investments.


Alessa Therapeutics is focused on development, clinical validation and commercialization of local, sustained drug delivery for solid organ disease.